Indian Drugs Controller General Dr. VG Somani on Tuesday allowed the Serum Institute of India (SII) to resume clinical trials (clinical trials) on candidates for the COVID-19 vaccine from Oxford. DCGI rescinded its earlier order prohibiting the selection of any candidate for the second and third stage trials.
However, DCGI has kept many other conditions including extra attention during the investigation. SII has also been asked by DGCI to submit information about treatment as per rules in dealing with adverse situations.
Earlier on September 11, DCGI directed the Serum Institute of India to stop the clinical trial of a possible vaccine for COVID-19 as the pharmaceutical giant AstraZeneca reported 'ill-health' of one person involved in the study. In countries, testing was stopped.